{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/fungal-skin-infection-body-groin/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"9df03477-c55a-5aee-a960-67b35e299585","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 65def4a6-6500-40b3-a9ca-c4fd4f742a1a --><h2>Changes</h2><!-- end field 65def4a6-6500-40b3-a9ca-c4fd4f742a1a -->","summary":null,"htmlStringContent":"<!-- begin item 2970de53-b32e-425c-886c-23b5c97e7f5c --><!-- begin field 4dab52dd-04eb-496b-9ee3-f82affe72b94 --><p><strong>May 2018</strong> — reviewed. A literature search was conducted in March 2018 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone restructuring. New nodes on Definition, Risk factors, Prevalence, Complications, and Prognosis have been added to the Background information section. The management recommendations have been updated in line with the current literature. The Prescribing Information section has been updated and expanded in line with current CKS style.</p><!-- end field 4dab52dd-04eb-496b-9ee3-f82affe72b94 --><!-- end item 2970de53-b32e-425c-886c-23b5c97e7f5c -->","topic":{"id":"10689662-2594-5bc5-aacc-6f0297698637","topicId":"0a9103d8-0e5e-4e22-8ed1-df6caa2888c6","topicName":"Fungal skin infection - body and groin ","slug":"fungal-skin-infection-body-groin","lastRevised":"Last revised in May 2018","chapters":[{"id":"f9a7dce7-311f-5a13-b2c1-c8cd43e2838e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"38743423-24de-522e-95bd-4e728ae9bff6","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"1f4590f4-eb5c-5ac7-ae22-883e2e53a6ad","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"9df03477-c55a-5aee-a960-67b35e299585","slug":"changes","fullItemName":"Changes"},{"id":"ef4d507c-dbca-5b25-8c50-9054ba69b8a6","slug":"update","fullItemName":"Update"}]},{"id":"6a5be767-a22b-5a75-9497-6b23cdd8af40","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"3333af1c-9f09-5390-98b9-e6486fea24ad","slug":"goals","fullItemName":"Goals"},{"id":"181bd2da-6331-5aa0-a497-5c0924b85b3d","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"997df680-1de7-5ca8-bd57-bfdc04fc5708","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4c32deb8-71c7-5ff4-8ea7-21d5afcf46f0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"291e3f39-4ba8-5287-b429-ab9096f614d1","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"7b7795b7-aa4b-5d16-9865-1f78a9aa7100","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"aa83eccd-4445-5d6a-85eb-2ec1398484cd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2993ff5f-d929-5124-b985-8bfe992b6123","slug":"definition","fullItemName":"Definition"},{"id":"e4bd4185-0aa9-5252-9ab8-9db4872de8e3","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"3b35bce6-3614-5272-b2bc-7dfec9933540","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c9f8364f-4629-5bf0-9e81-6b5bc8fa4dc9","slug":"complications","fullItemName":"Complications"},{"id":"db007724-80ee-5dd6-bb25-70aa7c0fa306","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"ddd3b119-1a06-5a24-a5c0-5bd1bdf86d33","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"a8efce2f-87d2-504f-a1d5-92cbd6d2e262","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"aa17d36a-2510-5bdd-b47b-2b2182e55fb9","slug":"assessment","fullItemName":"Assessment"},{"id":"625c3efb-8f3e-5c3f-9743-9fb04531f418","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"ad2cfebe-3930-561d-8516-fccbfb956fbb","fullItemName":"Management","slug":"management","subChapters":[{"id":"058eae7f-c108-5ee2-9421-bce49270bd1d","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"33c2524f-5b03-5298-b8b3-38f522d33ee3","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"3f5f1a54-036e-5ade-823a-9bc062fe3b65","slug":"topical-antifungals","fullItemName":"Topical antifungals"},{"id":"eb246451-6fc8-5e1c-af81-c0780be4ee3f","slug":"oral-terbinafine","fullItemName":"Oral terbinafine"},{"id":"118430c7-7a53-56e6-a43c-ee7b3140563a","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"},{"id":"0a620672-cf78-5a49-83c9-b25a3860e2b9","slug":"oral-griseofulvin","fullItemName":"Oral griseofulvin"}]},{"id":"6118e788-fa21-5752-864e-3f16ec7b305d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"bd6404d9-1abd-5cf0-99ee-b22f9fd18a84","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"b7837228-7495-51a3-8ea2-973b7ec42868","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"9bbac54b-39fb-522f-bfc7-ce8158baf074","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3c0e56a8-bb2e-5a9e-acbf-0fd43dda553c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f92ac5d0-593d-5b61-887b-d0be3a924870","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ececdb26-b868-5c5c-834a-dd5d3bdef118","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"ab97556e-8246-5384-b5eb-167898e7b53d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"1f4590f4-eb5c-5ac7-ae22-883e2e53a6ad","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"f45ff0d9-c79e-5430-aa1d-231c38878bab","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field bf445b9a-b150-4693-aafd-206c2c9b4a03 --><h3>Previous changes</h3><!-- end field bf445b9a-b150-4693-aafd-206c2c9b4a03 -->","summary":null,"htmlStringContent":"<!-- begin item fc87fdd2-8e9e-4c16-9e7e-ba78fb4917b2 --><!-- begin field 0059d9e3-5d34-452f-a4b2-42a04d0c80b6 --><p><strong>September 2014 </strong>— minor update. Text amended in the Prescribing information section on terbinafine, to state that a baseline liver function test is required before starting treatment with terbinafine.</p><p><strong>January 2014 </strong>— minor update. Text amended to include information from the manufacturer regarding how much clotrimazole to apply to the skin.</p><p><strong>December 2013 </strong>— minor update. Text amended to reflect that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has suspended the marketing authorisation for oral ketoconazole, and it should not be prescribed for the treatment of fungal infections.</p><p><strong>August 2013 </strong>— reviewed. A literature search was conducted in July 2013 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. No major changes to clinical recommendations have been made. Prescribing information has been added to support the prescribing of topical and oral antifungal treatments.</p><p><strong>August 2013 </strong>— minor update. Nizoral<sup>®</sup> (ketoconazole 2%) cream is no longer licensed for use in children.</p><p><strong>August 2013 </strong>— minor update. Text amended to reflect recent guidance from the European Medicines Agency (EMA) regarding the use of oral ketoconazole.</p><p><strong>November 2012</strong> — minor update. The links to the electronic medicines website (www.medicines.org.uk) have been updated.</p><p><strong>January 2012 </strong>— minor typographical error corrected. Issued in February 2012.</p><p><strong>August 2010 </strong>— minor update. Sulconazole 1% cream (Exelderm<sup>®</sup>) has been discontinued. The prescription has been removed. Issued in August 2010.</p><p><strong>May 2009 </strong>— minor update. Econazole 1% plus hydrocortisone 1% cream (Econacort<sup>®</sup>) has been discontinued. The prescription has been removed. Issued in June 2009.</p><p><strong>January to May 2009 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. Together with the CKS topics on <em>Fungal skin infection - foot</em> and <em>Fungal skin infection - scalp</em>, this CKS topic replaces the former topic on <em>Fungal skin infections.</em></p><p><strong>September 2008 </strong>— minor update. Correction to the <em>Changes </em>section. Issued in September 2008.</p><p><strong>August 2008 </strong>— minor update. Text amended to state that nystatin cream and ointment discontinued. Issued in August 2008.</p><p><strong>April 2008 </strong>— minor update. Text amended to reflect the most recent Medicines and Healthcare products Regulatory Agency (MHRA) guidance on oral ketoconazole.</p><p><strong>March 2008 </strong>— minor update. New text inserted regarding rare cases of changes in international normalized ratio (INR) when warfarin and oral terbinafine have been given concomitantly. Issued in March 2008.</p><p><strong>October to December 2005 </strong>— written. Validated in March 2006 and issued in May 2006.</p><!-- end field 0059d9e3-5d34-452f-a4b2-42a04d0c80b6 --><!-- end item fc87fdd2-8e9e-4c16-9e7e-ba78fb4917b2 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}